Skip to content

INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions

IgE-mediated Abdominal Pain

The goal of this study is to assess the efficacy of inhaled salbutamol to treat abdominal pain during food allergic reactions.

Patients experiencing abominal pain as a result of a food allergic reaction during a food challenge in the allergy clinic will be invited to participate to the study.

They will receive either 8 puffs of salbutamol (asthma inhaler) or 8 puffs of a placebo inhaler.

The abdominal pain will then be followed using a numeric scale to see if patients receiving the medication experienced a faster improvement compared to those receiving the placebo.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    6 to 55

Participation Criteria

Inclusion Criteria:

* Subjects aged between 6 to 55 years old.
* Undergoing an oral food challenge or an oral immunotherapy up-dosing visit for the diagnosis or treatment of an IgE-mediated food allergy.
* Previous confirmation of the food allergy by either skin prick tests (SPT) or serum specific IgE;
* Able to express the intensity of their pain using the NRS-11;
* Willing to comply with all study requirements.

Exclusion Criteria:

* Previous adverse reactions to salbutamol;
* Known hypersensitivity to salbutamol or placebo or any of their components;
* Any condition that could be considered a relative contra-indication to the use of salbutamol according to the investigator (e.g. patient with a history of hyperglycemia, arrhythmia or hypokalemia);
* Patients receiving beta-blockers or a daily / long-acting beta agonists;
* Patients needing to pass an anti-doping test for high-level sport in the following 24h.

Study Location

CHU Sainte-Justine
CHU Sainte-Justine
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Sabrina Cerro, BSc

[email protected]
514-345-4931
Study Sponsored By
St. Justine's Hospital
Participants Required
More Information
Study ID: NCT05653024